Researchers surveyed patients with blood cancer regarding what they value as the most important service in their hospice care.
According to results from the IMerge trial, 2 39.8% of patients treated with imetelstat achieved 8 weeks of transfusion independence compared with 15.0% of patients treated with placebo. Respondents ...